Symptoms and General Pathology

All Conditions

Neoplasms

Blood and Lymph Conditions

Immune System Diseases

Heart and Blood Diseases

Rare Diseases

Syndrome

Lymphoma

Multiple Myeloma

Neoplasms, Plasma Cell

Leukemia

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Leukemia, Lymphoid

Hematologic Neoplasms

Leukemia, Myeloid

Leukemia, Lymphocytic, Chronic, B-Cell

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Graft vs Host Disease

Hodgkin Disease

Myeloproliferative Disorders

Preleukemia

Myelodysplastic Syndromes

Primary Myelofibrosis

Hematologic Diseases

Chronic Graft Versus Host Disease

Lymphosarcoma

Myeloid Leukemia

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

Homologous Wasting Disease

Hodgkin Lymphoma

Acute Graft Versus Host Disease

Chronic Myeloproliferative Disorders

All Drugs and Chemicals

Tacrolimus

Thymoglobulin

Immunosuppressive Agents

Immunologic Factors

Calcineurin Inhibitors

Enzyme Inhibitors

Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis

Intravenous Tacrolimus 0.03 mg/kg/d, beginning day -3, where day 0 is the day of stem cell infusion or "transplant." Intravenous tacrolimus will be discontinued once the participant starts eating, and the drug will then be given orally at a dose of approximately 4 times the intravenous dose. Tacrolimus will be discontinued starting 100 days after transplant unless signs of acute and chronic GVHD develop or if severe toxicity occurs. Thymoglobulin will be given 0.5 mg/kg day-3, Thymoglobulin 1.5 mg/kg day -2, Thymoglobulin 2.5 mg/kg day -1. Thymoglobulin will be given intravenously over 6 hours.

Tacrolimus and Thymoglobulin

Zaid Al-Kadhimi, M.D.

The primary goal of the study is to determine the incidence and severity of acute Graft versus Host Disease (GVHD) following human leukocyte antigen (HLA) matched related donor Hematopoetic Stem Cell(HSC) transplant in patients with blood related cancers who receive the combination of tacrolimus and Thymoglobulin as GVHD prophylaxis. The investigators also will determine the safety of this combination in the first six months post transplant.

Secondary goals include determining the time to recovery of white blood cells and platelets (engraftment), determining the occurrence of opportunistic infections, defined as infection that occurs in people with weakened immune systems and caused by organisms that do not normally cause disease (fungal infections, pneumocystis carinii pneumonia (PCP), and viral infections), estimating the incidence of chronic GVHD at two years and the overall and disease free survival at two years.

Immune response will be assessed by means of immuno-correlative studies both prior to and at various points after transplant.

Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT

A Phase II Study of Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Related Donor Hematopoietic Cell Transplantation

Cumulative Incidence of grade II-V acute GVHD with relapse or NRM as competing risks

Counted the number of participants that experienced any type of grade 3 or higher toxicity.

Cumulative Incidence of grade III-V acute GVHD with relapse or NRM as competing risks

Cumulative Incidence of chronic GVHD with relapse or NRM as competing risks

The number of days until engraftment ("G500")

The number of days until engraftment ("PLT20")

Barbara Ann Karmanos Cancer Institute

Principal Investigator

Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis

Tacrolimus and Thymoglobulin: Intravenous Tacrolimus 0.03 mg/kg/d, beginning day -3, where day 0 is the day of stem cell infusion or "transplant." Intravenous tacrolimus will be discontinued once the participant starts eating, and the drug will then be given orally at a dose of approximately 4 times the intravenous dose. Tacrolimus will be discontinued starting 100 days after transplant unless signs of acute and chronic GVHD develop or if severe toxicity occurs. Thymoglobulin will be given 0.5 mg/kg day-3, Thymoglobulin 1.5 mg/kg day -2, Thymoglobulin 2.5 mg/kg day -1. Thymoglobulin will be given intravenously over 6 hours.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT	NCT01246206	Hematological M...	Tacrolimus and ...	18 Years - 70 Years	Barbara Ann Karmanos Cancer Institute
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT	NCT01246206	Hematological M...	Tacrolimus and ...	18 Years - 70 Years	Barbara Ann Karmanos Cancer Institute

Spots Global Cancer Trial Database for ● myelodysplastic syndromes,